SYNERGIC PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE COMBINATION OF AN ENZYME 5 ALPHA-REDUCTASE INHIBITOR AND AN ANGONIST OF 1 ALPHA-ADRENGER RECEPTORS.

摘要

The invention relates to various pharmaceutical compositions consisting of a synergic combination of a 5 ±-reductase enzyme inhibitor agent, such as the active ingredients finasteride or dutasteride, and an ±-adrenergic receptor antagonist agent, such as the active ingredients alfuzosine or doxazosine. Said agents are formulated in a single dosage unit to be orally administered in the form of tablets, and are suitable for treating benign prostatic hyperplasia, and for relieving the symptoms of said illness.